Investigating effects of IL-1Ra on B-cell function after stroke
Research type
Research Study
Full title
Defining effect of IL-1RA treatment after stroke on plasma biomarkers of B cell function and their relationship with catecholamines and clinical outcome
IRAS ID
217525
Contact name
Barry McColl
Contact email
Sponsor organisation
Salford Royal NHS Foundation Trust
Duration of Study in the UK
1 years, 0 months, 31 days
Research summary
Why?\tWe wish to establish if a treatment given to reduce inflammation after stroke affects the body’s immune system. This is relevant as we know that infection is common after stroke and has a direct influence on how well the patient recovers. \n \nWhat?\tWe have a number of samples of blood plasma left over from a clinical trial which compared a drug called interleukin-1 receptor antagonist (IL-1Ra) to dummy-drug (placebo). Using these samples we wish to measure concentrations of immunoglobulin (largest antibody in the circulation). This will give us information about how well the immune system was working at the time of stroke, whether IL-1Ra affected this. It will also tell us whether concentrations of immunoglobulin (Igm) taken in the first week after stroke is linked to stroke severity and recovery.\nWho?\tNo new participants will be recruited. The study will re-analysed existing samples only.\n\nWhere?\tThe samples are currently stored at Salford Royal NHS Foundation Trust. The samples are identified using only a unique code which is linked to clinical information about the participant e.g. risk factors, stroke severity and how well they recovered. All participant names have been removed. The samples will be transferred to our colleagues in the Roslin Institute in Edinburgh for analysis and the results will be sent back to the researchers in Salford where they will be linked to the clinical information. \n\nHow?\tThe study will commence on 1st December and is expected to take up to 1 year to complete.
REC name
North West - Preston Research Ethics Committee
REC reference
16/NW/0853
Date of REC Opinion
18 Nov 2016
REC opinion
Favourable Opinion